- Home
- AAMI vs DVAX Comparison
AAMI vs DVAX Comparison
Compare AAMI & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AAMI | DVAX |
|---|---|---|
| Founded | 1980 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | AAMI | DVAX |
|---|---|---|
| Price | $55.61 | $15.65 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 5 |
| Target Price | ★ $48.67 | $26.50 |
| AVG Volume (30 Days) | 186.2K | ★ 5.5M |
| Earning Date | 02-05-2026 | 02-19-2026 |
| Dividend Yield | ★ 0.07% | N/A |
| EPS Growth | ★ 45.00 | N/A |
| EPS | ★ 2.40 | N/A |
| Revenue | ★ $559,300,000.00 | $330,514,000.00 |
| Revenue This Year | $17.23 | $24.63 |
| Revenue Next Year | $24.02 | $15.85 |
| P/E Ratio | $22.91 | ★ N/A |
| Revenue Growth | 19.25 | ★ 26.73 |
| 52 Week Low | $22.60 | $9.20 |
| 52 Week High | $55.38 | $15.73 |
Technical Indicators
Market Signals| Indicator | AAMI | DVAX |
|---|---|---|
| Relative Strength Index (RSI) | 75.56 | 85.43 |
| Support Level | $52.00 | $15.56 |
| Resistance Level | $55.10 | $15.73 |
| Average True Range (ATR) | 1.99 | 0.07 |
| MACD | 0.44 | -0.11 |
| Stochastic Oscillator | 92.66 | 81.94 |
Price Performance
Historical ComparisonAbout AAMI Acadian Asset Management Inc.
Acadian Asset Management Inc is a holding company that operates a systematic investment management business through its subsidiary, that offers institutional investors across the globe access to a diversified array of systematic investment strategies designed to meet a range of risk and return objectives.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.